Skip to main content

Table 2 Clinical characteristics of PC GC with and without gene rearrangements

From: FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma

  No. of patients With rearrangements
n = 9 (%)
Without rearrangements
n = 19 (%)
Pa
Age (years) 0.371
 < 60 20 5 (55.6%) 15 (78.9%)  
 ≥ 60 8 4 (44.4%) 4 (21.1%)  
Gender 0.249
Male 17 7 (77.8%) 10 (52.6%)  
Female 11 2 (22.2%) 9 (47.4%)  
AJCC 0.010
 IIIA–B 17 2 (22.2%) 15 (78.9%)  
 IIIC 11 7 (77.8%) 4 (21.1%)  
T stage 1.000
 3 17 5 (55.6%) 12 (63.2%)  
 4a–4b 11 4 (44.4%) 7 (36.8%)  
N stage 0.001
 1–3a 19 2 (22.2%) 17 (89.5%)  
 3b 9 7 (77.8%) 2 (10.5%)  
Tumor size (cm)  
 ≤ 4 10 4 (44.4%) 6 (31.6%) 0.677
 > 4 18 5 (55.6%) 13 (68.4%)  
Tumor location 0.370
 Upper 7 4 (44.4%) 3 (15.8%)  
 Middle 7 1 (11.1%) 6 (31.6%)  
 Lower 10 3 (33.3%) 7 (36.8%)  
 Overlap 4 1 (11.1%) 3 (15.8%)  
PD-L1 0.689
 Negative 15 4 (44.4%) 11 (57.9%)  
 Positive 13 5 (55.6%) 8 (42.1%)  
PD-1 1.000
 Negative 22 7 (77.8%) 15 (78.9%)  
 Positive 6 2 (22.2%) 4 (21.1%)  
CD3 0.420
 Low 14 3 (33.3%) 11 (57.9%)  
 High 14 6 (66.7%) 8 (42.1%)  
  1. AJCC American Joint Committee on Cancer, PC poorly cohesive
  2. aFisher’s exact test was used in statistical analyses. Values in italic are statistically significant